Investing.com - Dare Bioscience (NASDAQ: DARE) reported second quarter EPS of $-0.1000, in line with the analyst estimate of $-0.1000. Revenue for the quarter came in at $850K versus the consensus estimate of $1.1M.
Dare Bioscience's stock price closed at $0.7300. It is down -26.6600% in the last 3 months and down -40.8600% in the last 12 months.
Dare Bioscience saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Dare Bioscience's stock price’s past reactions to earnings here.
According to InvestingPro, Dare Bioscience's Financial Health score is "fair performance".
Check out Dare Bioscience's recent earnings performance, and Dare Bioscience's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar